Conjugate Vaccines

Conjugate Vaccines Market Outlook

The global conjugate vaccines market is projected to reach approximately USD 15 billion by 2035, growing at a CAGR of around 10% during the forecast period of 2025 to 2035. The surge in this market can be attributed to the increasing prevalence of infectious diseases, growing awareness about vaccine importance, and advancements in vaccine technology. Additionally, the rise in government initiatives aimed at immunization programs and the growing demand for pediatric vaccines are significant contributors to the market's expansion. The recent focus on targeted vaccines for specific populations, such as the elderly and individuals with comorbid conditions, also plays a critical role in driving the market forward. Furthermore, the development of new conjugate vaccines tailored for various diseases is likely to enhance the growth trajectory of this market.

Growth Factor of the Market

The growth of the conjugate vaccines market is primarily driven by several key factors. Firstly, the increasing incidence of infectious diseases such as pneumococcal disease, meningitis, and Haemophilus influenzae type b (Hib) infections is propelling the demand for effective vaccination solutions. Secondly, advancements in biotechnology and vaccine formulation processes have led to the development of more efficient and safer conjugate vaccines. Thirdly, the rising awareness about vaccination benefits among the population, alongside government initiatives promoting immunization, is fostering greater acceptance and uptake of these vaccines. Moreover, the COVID-19 pandemic has highlighted the importance of vaccination, thus accelerating research and development in vaccine technology. Lastly, the growing geriatric population, which is more susceptible to various infectious diseases, is further driving the demand for conjugate vaccines.

Key Highlights of the Market

• The conjugate vaccines market is expected to witness a substantial growth rate over the next decade, primarily due to increasing infectious disease incidence.
• Technological advancements in vaccine development are paving the way for the introduction of novel conjugate vaccines.
• Government initiatives and programs focusing on immunization are enhancing vaccine coverage globally.
• Rising awareness about the importance of vaccinations among populations is contributing to market growth.
• The growing geriatric population is creating a higher demand for effective vaccines targeting age-related diseases.

By Product Type

Monovalent Conjugate Vaccines:

Monovalent conjugate vaccines are designed to target a single pathogen and are crucial for the prevention of specific diseases. These vaccines have proven effective in treating infections like pneumococcal disease, where a single strain is responsible for most cases. The effectiveness of monovalent vaccines is often attributed to their focused approach, allowing for a more robust immune response against a specific antigen. The success of vaccines like the pneumococcal conjugate vaccine (PCV) has led to increased investments in developing similar monovalent vaccines for other diseases. As a result, this segment is expected to witness substantial growth, particularly in regions with high disease prevalence.

Multivalent Conjugate Vaccines:

Multivalent conjugate vaccines offer protection against multiple strains of a pathogen, making them particularly effective against diseases that exhibit considerable strain variation. Such vaccines combine several polysaccharide antigens, leading to a broader immune response. The development of vaccines against serogroups of bacteria, such as Neisseria meningitidis, is a prominent example, as these vaccines provide defenses against several meningococcal disease strains simultaneously. The increasing incidence of multistrain infections is driving demand for these vaccines, which is anticipated to fuel the growth of the multivalent conjugate segment significantly.

Combination Conjugate Vaccines:

Combination conjugate vaccines integrate multiple vaccines into a single shot, enhancing convenience for patients and healthcare providers. This type of vaccine aims to reduce the number of injections needed, thereby improving compliance, particularly in pediatric populations. Products like DTPa-Hib-IPV-HepB are examples of combination vaccines that protect against various diseases in one administration. As healthcare systems strive for increased efficiency and improved public health outcomes, the demand for combination vaccines is expected to rise, which will positively impact the segment's growth within the conjugate vaccines market.

Conjugate Vaccines for Pediatric Use:

Pediatric conjugate vaccines are specifically formulated to meet the immunization needs of infants and children. Given the vulnerability of younger populations to serious infections, the development of effective pediatric conjugate vaccines is critical. Vaccines such as the 13-valent pneumococcal conjugate vaccine (PCV13) have shown remarkable efficacy in preventing pneumonia and meningitis in children. The increasing emphasis on childhood immunization programs and government recommendations for routine vaccinations are expected to support market growth in this segment significantly.

Conjugate Vaccines for Adult Use:

Conjugate vaccines for adult use have gained traction in recent years, particularly for preventing infections that affect older populations. Diseases such as pneumococcal infections and meningococcal disease are prevalent among adults, especially those with underlying health conditions. The introduction of vaccines like the 23-valent pneumococcal polysaccharide vaccine (PPSV23) caters to this demographic. As awareness regarding the importance of adult vaccination continues to grow, coupled with an aging global population, the market for conjugate vaccines tailored for adults is expected to expand significantly.

By Application

Infectious Diseases:

Infectious diseases remain the primary application for conjugate vaccines, targeting pathogens that cause significant morbidity and mortality worldwide. Vaccines against bacterial infections such as pneumococcus and meningococcus have been instrumental in reducing disease burden. The effectiveness of conjugate vaccines in eliciting long-lasting immunity and their role in herd immunity further underscore their importance in public health initiatives aimed at controlling infectious diseases. The rising incidence of antibiotic-resistant infections has also highlighted the need for effective vaccination strategies, making this segment a focal point for market growth.

Cancer:

Conjugate vaccines are emerging as a novel approach in cancer immunotherapy, aiming to stimulate the immune system to target and destroy cancer cells. These vaccines can carry tumor-associated antigens, allowing for a targeted immune response that enhances anti-tumor activity. Research and clinical trials are underway to explore the efficacy of conjugate vaccines in various cancers, including melanoma and bladder cancer. Given the increasing prevalence of cancer globally, the potential of conjugate vaccines in oncology is expected to create significant opportunities within this application segment.

Allergies:

Allergy management is another area where conjugate vaccines are being investigated, particularly for desensitization to pollen, dust mites, and other allergens. These vaccines aim to modify the immune response to specific allergens, reducing the severity of allergic reactions. Ongoing research is focused on developing effective conjugate vaccines that can provide long-term relief from allergy symptoms. As the incidence of allergic conditions continues to rise, particularly among children, the potential market for conjugate vaccines in allergy treatment appears promising.

Respiratory Diseases:

Respiratory diseases, including influenza and RSV (Respiratory Syncytial Virus), pose significant health risks, especially in vulnerable populations such as infants and the elderly. Conjugate vaccines targeting pathogens responsible for respiratory infections are being developed to enhance immunity and reduce transmission. The COVID-19 pandemic has further underlined the need for effective respiratory disease vaccines, spurring research in this area. As awareness of respiratory disease prevention grows, the conjugate vaccines designed for this application are anticipated to witness considerable growth in the coming years.

Others:

This category encompasses a range of applications where conjugate vaccines may be utilized, including travel-related vaccinations or vaccines aiming to target specific endemic diseases in certain regions. The flexible nature of conjugate vaccine development allows for innovations tailored to emerging health threats. As global travel increases and new infectious diseases arise, the ability for conjugate vaccines to adapt to these challenges will be critical. This segment will benefit from the need for vaccines that address localized health concerns, thus presenting opportunities for market growth.

By Distribution Channel

Hospitals & Clinics:

Hospitals and clinics remain a primary distribution channel for conjugate vaccines, providing essential vaccination services to patients. The presence of healthcare professionals ensures that vaccines are administered safely and effectively, with necessary monitoring for adverse reactions. This channel facilitates access to vaccines for patients who may require additional medical evaluations or those with pre-existing health conditions. The focus on providing comprehensive immunization services within healthcare institutions promotes trust and increases the likelihood of vaccination, thereby enhancing market growth in this segment.

Retail Pharmacies:

Retail pharmacies are gaining prominence as accessible points for administering conjugate vaccines, particularly for adult populations. The convenience of walk-in vaccinations and extended hours offered by pharmacies appeals to consumers looking for flexibility in healthcare services. Retail pharmacies often provide essential information about vaccines, encouraging patients to take advantage of immunization opportunities. This trend is likely to continue as pharmacies expand their roles in public health initiatives, making them a vital distribution channel for conjugate vaccines.

Online Pharmacies:

The rise of online pharmacies has revolutionized the way consumers access healthcare products, including vaccines. While vaccines typically require administration by a healthcare professional, online pharmacies play a crucial role in providing information about available vaccines and facilitating appointments for vaccination services. The growing trend of telemedicine and digital health solutions is likely to enhance the connection between consumers and vaccination services, further integrating online pharmacies into the distribution channels for conjugate vaccines.

Others:

Other distribution channels include governmental health programs and mobile vaccination units that facilitate access to conjugate vaccines for underserved populations. These channels play a crucial role in public health initiatives aimed at reaching communities with limited access to healthcare services. Collaboration with NGOs and community health organizations also enhances the distribution of vaccines in remote areas. This diversified approach to distribution ensures that conjugate vaccines reach a broader audience, ultimately contributing to improved vaccination rates and public health outcomes.

By Ingredient Type

Protein Conjugates:

Protein conjugates are a significant component of many conjugate vaccines, where polysaccharides are linked to proteins to enhance immune response. The combination allows the immune system to recognize and respond more effectively to the polysaccharide antigens, leading to better long-term immunity. Vaccines like the pneumococcal conjugate vaccine utilize this approach, demonstrating the efficacy of protein conjugation in preventing severe infections. As research progresses, the development of novel protein conjugates is expected to emerge, driving growth in this ingredient type.

Polysaccharide Conjugates:

Polysaccharide conjugates form the backbone of many conjugate vaccines by providing the necessary antigens for immune recognition. These conjugates are designed to elicit strong immune responses against encapsulated bacteria, which are often difficult to target with traditional vaccines. The use of polysaccharide conjugates has been instrumental in the success of vaccines for diseases like meningitis and pneumococcal infections. With ongoing advancements in polysaccharide technology, this ingredient type remains critical for the formulation of effective conjugate vaccines.

Toxoid Conjugates:

Toxoid conjugates are another critical component of certain conjugate vaccines, where inactivated bacterial toxins are used to evoke an immune response without causing disease. This approach has been effective in developing vaccines against diseases caused by toxin-producing bacteria. For instance, the diphtheria and tetanus toxoid conjugate vaccines have demonstrated success in immunization efforts. As research continues to explore the potential of toxoid conjugates, this segment is expected to see growth and innovation within the conjugate vaccines market.

Recombinant Conjugates:

Recombinant conjugates leverage genetic engineering techniques to produce antigens that can be linked to carrier proteins. This innovative approach allows for the design of vaccines with enhanced safety profiles and effectiveness. Recombinant technology has already been utilized in the development of vaccines for diseases like hepatitis B and HPV. As the biotechnology sector advances, the potential for recombinant conjugates in conjugate vaccines presents significant opportunities for market growth.

Synthetic Conjugates:

Synthetic conjugates represent a cutting-edge approach to vaccine development where synthetic chemistry is employed to create antigenic components. This method allows for the precise control of the immunogenic properties of the vaccine, potentially leading to more effective and safer vaccines. Although still in the early stages of development, synthetic conjugates hold promise for addressing emerging infectious diseases and enhancing vaccine portfolios. As research advances, this ingredient type may play a critical role in the future of conjugate vaccines.

By Region

The North American region is anticipated to dominate the conjugate vaccines market, holding a significant share due to robust healthcare infrastructure and high vaccination rates. The United States, in particular, has established extensive immunization programs that promote the uptake of conjugate vaccines. The market is expected to maintain a growth rate of around 9% CAGR during the forecast period, driven by continuous innovations in vaccine development and increased awareness of childhood immunization. Additionally, government initiatives supporting vaccination initiatives contribute to the growth of the conjugate vaccines market in this region.

In Europe, the conjugate vaccines market is expected to witness steady growth, driven by increasing healthcare investment and a strong emphasis on preventive healthcare. Countries like Germany, France, and the United Kingdom are leading the adoption of conjugate vaccines, particularly in pediatric immunization programs. The European market is projected to grow at a CAGR of approximately 8% during the forecast period. The rising awareness of infectious diseases, alongside efforts to improve vaccination coverage, will further propel the demand for conjugate vaccines across the region. The collaborative efforts between public health authorities and pharmaceutical companies will also facilitate market growth in Europe.

Opportunities

The conjugate vaccines market is poised to harness numerous opportunities that can spur growth in the coming years. One of the most significant opportunities lies in expanding vaccination coverage in developing regions where access to vaccines remains limited. Public health initiatives aiming to improve healthcare infrastructure and vaccination outreach may lead to increased demand for conjugate vaccines, particularly for childhood immunization. Collaborations between governments, NGOs, and healthcare organizations can facilitate the distribution of these vaccines, ensuring they reach underserved populations. Additionally, the emergence of new infectious diseases warrants the urgent need for effective vaccination solutions, creating opportunities for the development of conjugate vaccines targeting these health threats.

Another critical opportunity exists in the realm of innovation and research within the conjugate vaccines market. As scientific advancements continue to evolve, the potential for creating novel conjugate vaccines that address emerging health concerns is immense. Research into new adjuvants and delivery systems could enhance the efficacy of existing vaccines and lead to the creation of new formulations. Furthermore, the trend towards personalized medicine presents opportunities for developing tailored conjugate vaccines that cater to specific populations based on genetic, immunological, or epidemiological factors. By tapping into these opportunities, stakeholders in the conjugate vaccines market can ensure sustainable growth and long-term impact on public health outcomes.

Threats

The conjugate vaccines market faces several threats that could hinder growth and impact public health efforts. One of the primary threats is the rising prevalence of vaccine hesitancy, fueled by misinformation and mistrust regarding vaccine safety and efficacy. This trend can lead to lower vaccination rates, increasing the risk of disease outbreaks and undermining public health initiatives aimed at controlling infectious diseases. Additionally, the emergence of new pathogens or variants of existing pathogens may pose challenges to current conjugate vaccine formulations, necessitating rapid responses from the vaccine development sector. The constant evolution of diseases can create uncertainty in market demand and highlight the need for ongoing research and development.

Another threat to the conjugate vaccines market is the competitive landscape, especially the presence of alternative vaccine technologies such as mRNA vaccines and viral vector-based vaccines. As these new technologies show promising results in clinical trials and receive regulatory approvals, they could divert funding and attention away from traditional conjugate vaccines. Furthermore, the complex regulatory environment surrounding vaccine approvals and the stringent manufacturing processes may also slow down the pace of innovation, posing a restraint on market growth. Addressing these threats will be crucial for maintaining the continuity and sustainability of the conjugate vaccines market.

Competitor Outlook

• Pfizer Inc.
• Sanofi Pasteur
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Novartis AG
• Johnson & Johnson
• Serum Institute of India Pvt. Ltd.
• Bharat Biotech International Limited
• Moderna, Inc.
• Biocon Limited
• Vaxart, Inc.
• Inovio Pharmaceuticals, Inc.
• Emergent BioSolutions Inc.
• AbbVie Inc.
• Regeneron Pharmaceuticals, Inc.

The conjugate vaccines market's competitive landscape is marked by a dynamic environment with numerous companies engaged in the development and commercialization of these critical healthcare products. Major pharmaceutical corporations such as Pfizer, Merck, and GlaxoSmithKline have established themselves as key players in the conjugate vaccines domain, leveraging their extensive research capabilities and global reach. These companies focus on innovation and are investing significantly in research and development to create next-generation conjugate vaccines that address emerging health threats. Furthermore, partnerships and collaborations with academic institutions and public health organizations are becoming increasingly common to expedite vaccine development processes and enhance market access.

Emerging biotechnology firms are also making their mark within the conjugate vaccines market, bringing forth innovative solutions and technologies. Companies like Moderna and Inovio Pharmaceuticals are exploring new vaccine platforms and delivery systems, aiming to enhance the efficacy and safety of conjugate vaccines. Additionally, regional players such as Serum Institute of India and Bharat Biotech are expanding their vaccine portfolios to cater to the specific needs of local populations. This competitive landscape highlights the importance of agility and adaptability in the ever-evolving vaccine market, as stakeholders strive to meet public health demands and stay ahead of competitors.

Notably, companies such as Sanofi Pasteur and Merck are renowned for their successful conjugate vaccines targeting diseases like pneumococcus and meningococcus. Sanofi's Pneumococcal Conjugate Vaccine (PCV) has made a significant impact on reducing disease burden in children, while Merck's Meningococcal Conjugate Vaccine has enhanced protection against meningococcal disease. These major players not only drive revenue and market growth but also play a critical role in shaping national vaccination policies and programs. Their commitment to quality and safety reinforces public confidence in vaccines, ultimately benefiting the conjugate vaccines market as a whole.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 AbbVie Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Novartis AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Vaxart, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Moderna, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Biocon Limited
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Sanofi Pasteur
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 GlaxoSmithKline plc
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Emergent BioSolutions Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Inovio Pharmaceuticals, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Regeneron Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Serum Institute of India Pvt. Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Bharat Biotech International Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Conjugate Vaccines Market, By Application
    • 6.1.1 Infectious Diseases
    • 6.1.2 Cancer
    • 6.1.3 Allergies
    • 6.1.4 Respiratory Diseases
    • 6.1.5 Others
  • 6.2 Conjugate Vaccines Market, By Product Type
    • 6.2.1 Monovalent Conjugate Vaccines
    • 6.2.2 Multivalent Conjugate Vaccines
    • 6.2.3 Combination Conjugate Vaccines
    • 6.2.4 Conjugate Vaccines for Pediatric Use
    • 6.2.5 Conjugate Vaccines for Adult Use
  • 6.3 Conjugate Vaccines Market, By Ingredient Type
    • 6.3.1 Protein Conjugates
    • 6.3.2 Polysaccharide Conjugates
    • 6.3.3 Toxoid Conjugates
    • 6.3.4 Recombinant Conjugates
    • 6.3.5 Synthetic Conjugates
  • 6.4 Conjugate Vaccines Market, By Distribution Channel
    • 6.4.1 Hospitals & Clinics
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Conjugate Vaccines Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Conjugate Vaccines market is categorized based on

By Product Type

• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccines
• Combination Conjugate Vaccines
• Conjugate Vaccines for Pediatric Use
• Conjugate Vaccines for Adult Use

By Application

• Infectious Diseases
• Cancer
• Allergies
• Respiratory Diseases
• Others

By Distribution Channel

• Hospitals & Clinics
• Retail Pharmacies
• Online Pharmacies
• Others

By Ingredient Type

• Protein Conjugates
• Polysaccharide Conjugates
• Toxoid Conjugates
• Recombinant Conjugates
• Synthetic Conjugates

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• Sanofi Pasteur
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Novartis AG
• Johnson & Johnson
• Serum Institute of India Pvt. Ltd.
• Bharat Biotech International Limited
• Moderna, Inc.
• Biocon Limited
• Vaxart, Inc.
• Inovio Pharmaceuticals, Inc.
• Emergent BioSolutions Inc.
• AbbVie Inc.
• Regeneron Pharmaceuticals, Inc.